cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1987Research ArticleАРТЕРИАЛЬНАЯ ГИПЕРТОНИЯARTERIAL HYPERTENSIONОсобенности антигипертензивной терапии в профилактике развития гипертрофии левого желудочка у больных гипертонической болезнью при высокой приверженности лечениюAntihypertensive therapy and left ventricular hypertrophy prevention in patients with essential arterial hypertension and high treatment complianceКозиоловаН. А.KoziolovaN. A.

заведующая кафедрой внутренних болезней педиатрического и стоматологического факультетов

Пермь, Тел.: 8 902 471 47 85, факс: 8 3422 44 29 49

Perm

nakoziolova@mail.ruШатуноваИ. М.ShatunovaI. M.

заведующая кардиологическим кабинетом поликлиники

Москва

ЛазаревИ. А.LazarevI. A.

заведующий терапевтическим отделением № 1, заместитель главного врача

Москва

Пермская государственная медицинская академия имени академика Е.А. ВагнераРоссияAcad. E.A. Vagner State Medical AcademyRussian FederationПоликлиника ОАО “ГАЗПРОМ”РоссияGazprom PoliclinicRussian Federation20110101197010749Copyright © Козиолова Н.А., Шатунова И.М., Лазарев И.А., 19701970Козиолова Н.А., Шатунова И.М., Лазарев И.А.Koziolova N.A., Shatunova I.M., Lazarev I.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1987

Цель. Определить особенности антигипертензивной терапии (АГТ) в профилактике развития гипертрофии левого желудочка (ГЛЖ) у больных гипертонической болезнью (ГБ) без поражения органов-мишеней (ПОМ) при высокой приверженности лечению. Материал и методы. Проведено когортное, проспективное исследование. В исследование включены 428 больных ГБ без ПОМ. Длительность наблюдения составила 8,8±2,6 лет. Результаты. Частота развития ГЛЖ в дебюте при высокой приверженности лечению составила 36,9 %. Интенсивность АГТ была выше в группе (гр.) больных с ремоделированием ЛЖ, и характеризовалась более высокой частотой использования комбинированной АГТ и b-адреноблокаторов. Заключение. У больных ГБ на фоне высокой приверженности лечению частота возникновения ГЛЖ ниже, чем в общей популяции. Более высокая интенсивность АГТ в гр. больных с ГЛЖ, вероятно, связана с частичной резистентностью к ней у этой категории больных.

Aim. To investigate the features of antihypertensive therapy (AHT), as a method of left ventricular hypertrophy (LVH) prevention, in patients with essential arterial hypertension (EAH), absence of target organ damage (TOD), and high treatment compliance. Material and methods. This prospective cohort study included 428 patients with EAH and no TOD (mean followup 8,8±2,6 years). Results. In patients with EAH, and high treatment compliance, LVH incidence was 36,9 %. AHT was more aggressive in patients with LV remodelling, and was characterised by higher rates of combined treatment or b-adrenoblocker treatment. Conclusion. In EAH patients with high treatment compliance, LVH incidence was lower than in general population. More aggressive AHT among patients with LVH could be explained by potential therapy resistance in this clinical group.

гипертоническая болезньгипертрофия миокарда левого желудочкаприверженность лечениюантигипертензивная терапияb-адреноблокаторыпрофилактикаEssential arterial hypertensionleft ventricular hypertrophytreatment complianceantihypertensive therapybeta-adrenoblockerspreventionReferencesFerreira Filho C, Abreu LC, Valenti VE, et al. Anti-hypertensive drugs have different effects on ventricular hypertrophy regression. Clinics (Sao Paulo) 2010; 65(7): 723-8.Ferreira Filho C, Abreu LC, Valenti VE, et al. Anti-hypertensive drugs have different effects on ventricular hypertrophy regression. Clinics (Sao Paulo) 2010; 65(7): 723-8.Weir MR, Townsend RR. What is left ventricular hypertrophy and is there a reason to regress left ventricular hypertrophy? J Clin Hypertens (Greenwich) 2009; 11(8): 407-10.Weir MR, Townsend RR. What is left ventricular hypertrophy and is there a reason to regress left ventricular hypertrophy? J Clin Hypertens (Greenwich) 2009; 11(8): 407-10.Simpson HJ, Gandy SJ, Houston JG, et al. Left ventricular hypertrophy: reduction of blood pressure already in the normal range further regresses left ventricular mass. Heart 2010; 96(2): 148-52.Simpson HJ, Gandy SJ, Houston JG, et al. Left ventricular hypertrophy: reduction of blood pressure already in the normal range further regresses left ventricular mass. Heart 2010; 96(2): 148-52.Solomon SD, Appelbaum E, Manning WJ, et al. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009; 119(4): 530-7.Solomon SD, Appelbaum E, Manning WJ, et al. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009; 119(4): 530-7.Gray RP, Turner MA, Sheridan DJ, Fry CH. The role of angiotensin receptor-1 blockade on electromechanical changes induced by left ventricular hypertrophy and its regression. Cardiovasc Res 2007; 73(3): 539-48.Gray RP, Turner MA, Sheridan DJ, Fry CH. The role of angiotensin receptor-1 blockade on electromechanical changes induced by left ventricular hypertrophy and its regression. Cardiovasc Res 2007; 73(3): 539-48.Munger MA. Use of Angiotensin receptor blockers in cardiovascular protection: current evidence and future directions. P T 2011; 36(1): 22-40.Munger MA. Use of Angiotensin receptor blockers in cardiovascular protection: current evidence and future directions. P T 2011; 36(1): 22-40.Simko F, Pechanova O. Remodelling of the heart and vessels in experimental hypertension: advances in protection. J Hypertens 2010; 28 Suppl 1: S1-6.Simko F, Pechanova O. Remodelling of the heart and vessels in experimental hypertension: advances in protection. J Hypertens 2010; 28 Suppl 1: S1-6.Wachtell K, Okin PM, Olsen MH, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. Circulation 2007; 116(7): 700-5.Wachtell K, Okin PM, Olsen MH, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. Circulation 2007; 116(7): 700-5.Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004; 292(19): 2343-9.Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004; 292(19): 2343-9.Fuchs FD, Fuchs SC, Moreira LB, et al. A comparison between diuretics and angiotensin-receptor blocker agents in patients with stage I hypertension (PREVER-treatment trial): study protocol for a randomized double-blind controlled trial. Trials 2011; 12: 53.Fuchs FD, Fuchs SC, Moreira LB, et al. A comparison between diuretics and angiotensin-receptor blocker agents in patients with stage I hypertension (PREVER-treatment trial): study protocol for a randomized double-blind controlled trial. Trials 2011; 12: 53.Poppe KK, Doughty RN, Yu CM, et al. MeRGE collaborators. Understanding differences in results from literature-based and individual patient meta-analyses: an example from meta-analyses of observational data. Int J Cardiol 2011; 148(2): 209-13.Poppe KK, Doughty RN, Yu CM, et al. MeRGE collaborators. Understanding differences in results from literature-based and individual patient meta-analyses: an example from meta-analyses of observational data. Int J Cardiol 2011; 148(2): 209-13.Kaul S, Diamond GA, Trial and error. How to avoid commonly encountered limitations of published clinical trials. JACC 2010; 55(5): 415-27.Kaul S, Diamond GA, Trial and error. How to avoid commonly encountered limitations of published clinical trials. JACC 2010; 55(5): 415-27.Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24: 67-74.Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24: 67-74.Chobanian AV, Bakris GL, Black HR, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52.Chobanian AV, Bakris GL, Black HR, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52.Devereux RB, Bella J, Boman K, et al. Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. Blood Press 2001; 10(2): 74-82.Devereux RB, Bella J, Boman K, et al. Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. Blood Press 2001; 10(2): 74-82.Santa-Helena ET, Nemes MI, Eluf Neto J. Risk factors associated with non-adherence to anti-hypertensive medication among patients treated in family health care facilities. Cad Saude Publica 2010; 26(12): 2389-98.Santa-Helena ET, Nemes MI, Eluf Neto J. Risk factors associated with non-adherence to anti-hypertensive medication among patients treated in family health care facilities. Cad Saude Publica 2010; 26(12): 2389-98.Morgado M, Rolo S, Macedo AF, et al. Predictors of uncontrolled hypertension and antihypertensive medication nonadherence. J Cardiovasc Dis Res 2010; 1(4): 196-202.Morgado M, Rolo S, Macedo AF, et al. Predictors of uncontrolled hypertension and antihypertensive medication nonadherence. J Cardiovasc Dis Res 2010; 1(4): 196-202.Zhong J, Basu R, Guo D, et al. Angiotensin-Converting Enzyme 2 Suppresses Pathological Hypertrophy, Myocardial Fibrosis, and Cardiac Dysfunction. Circulation 2010; 122(7): 717-28.Zhong J, Basu R, Guo D, et al. Angiotensin-Converting Enzyme 2 Suppresses Pathological Hypertrophy, Myocardial Fibrosis, and Cardiac Dysfunction. Circulation 2010; 122(7): 717-28.Gallego-Delgado J, Lazaro A, Osende JI, et al. Proteomic analysis of early left ventricular hypertrophy secondary to hypertension: modulation by antihypertensive therapies. J Am Soc Nephrol 2006; 17(12 Suppl 3): S159-64.Gallego-Delgado J, Lazaro A, Osende JI, et al. Proteomic analysis of early left ventricular hypertrophy secondary to hypertension: modulation by antihypertensive therapies. J Am Soc Nephrol 2006; 17(12 Suppl 3): S159-64.Kohno M, Yokokawa K, Minami M, et al. Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors. Am J Med 1999; 106(5): 544-9.Kohno M, Yokokawa K, Minami M, et al. Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors. Am J Med 1999; 106(5): 544-9.Hallberg P, Lind L, Billberger K, et al. Transforming growth factor beta1 genotype and change in left ventricular mass during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). Clin Cardiol 2004; 27(3): 169-73.Hallberg P, Lind L, Billberger K, et al. Transforming growth factor beta1 genotype and change in left ventricular mass during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). Clin Cardiol 2004; 27(3): 169-73.Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363: 2049-51.Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363: 2049-51.Coca A, De la Sierra A. Salt sensitivity and left ventricular hypertrophy. Adv Exp Med Biol 1997; 432: 91-101.Coca A, De la Sierra A. Salt sensitivity and left ventricular hypertrophy. Adv Exp Med Biol 1997; 432: 91-101.Bhattacharya SK, Gandhi MS, Kamalov G, et al. Myocardial remodeling in low-renin hypertension: molecular pathways to cellular injury in relative aldosteronism. Curr Hypertens Rep 2009; 11(6): 412-20.Bhattacharya SK, Gandhi MS, Kamalov G, et al. Myocardial remodeling in low-renin hypertension: molecular pathways to cellular injury in relative aldosteronism. Curr Hypertens Rep 2009; 11(6): 412-20.Минушкина Л.О., Никитин А.Г., Бражник В.А. и др. Гипертрофия миокарда у больных гипертонической болезнью: роль генетического полиморфизма b-адренореактивных структур. Кардиология 2010; 50(1): 9-15.Минушкина Л.О., Никитин А.Г., Бражник В.А. и др. Гипертрофия миокарда у больных гипертонической болезнью: роль генетического полиморфизма b-адренореактивных структур. Кардиология 2010; 50(1): 9-15.Kronish IM, Woodward M, Sergie Z, et al. Meta-analysis: impact of drug class on adherence to antihypertensives. Circulation 2011; 123(15): 1611-21.Kronish IM, Woodward M, Sergie Z, et al. Meta-analysis: impact of drug class on adherence to antihypertensives. Circulation 2011; 123(15): 1611-21.Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens 2005; 23: 2101-7.Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens 2005; 23: 2101-7.Berglund T, Dahlöf B, Sever P, et al. Differential regression of electrocardiographic left ventricular hypertrophy by amlodipine versus atenolol in the ASCOT-trial. J Hypertens 2008; 26(suppl 1): S254. Abstract PS17/TUE/05.Berglund T, Dahlöf B, Sever P, et al. Differential regression of electrocardiographic left ventricular hypertrophy by amlodipine versus atenolol in the ASCOT-trial. J Hypertens 2008; 26(suppl 1): S254. Abstract PS17/TUE/05.Milan A, Caserta MA, Avenatti E, et al. Anti-hypertensive drugs and left ventricular hypertrophy: a clinical update. Int Emerg Med 2010; 5(6): 469-79.Milan A, Caserta MA, Avenatti E, et al. Anti-hypertensive drugs and left ventricular hypertrophy: a clinical update. Int Emerg Med 2010; 5(6): 469-79.

The authors declare that there are no conflicts of interest present.